Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 9:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Gralise Clear all
Withdrawn Phase 2 Interventional

PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing

NCT03423264
View directory record Official record
Conditions
Oropharyngeal Cancer, HPV-Related Squamous Cell Carcinoma
Interventions
Gabapentin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Sep 22, 2026, 9:05 PM EDT
Terminated Phase 4 Interventional Results available

Efficacy of Gralise® for Chronic Pelvic Pain

NCT01678911
View directory record Official record
Conditions
Irritable Bowel Syndrome, Ulcerative Colitis, Interstitial Cystitis, Prostatitis, Pelvic Pain
Interventions
Gralise
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Sep 22, 2026, 9:05 PM EDT
Withdrawn Phase 4 Interventional

Improving Pain Management After Total Shoulder Replacement Using Bupivacaine Liposome

NCT04134442
View directory record Official record
Conditions
Osteoarthritis of the Shoulder, Shoulder Pain, Pain, Postoperative
Interventions
Bupivacaine Liposome Injection, Standard Therapy
Drug · Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Sep 22, 2026, 9:05 PM EDT
Recruiting Phase 2 Interventional

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

NCT06591091
View directory record Official record
Conditions
Depression
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 22, 2026, 9:05 PM EDT
Completed Phase 1 Interventional

Maintenance Gabapentin to Prolong Pregnancy.

NCT02056899
View directory record Official record
Conditions
Preterm Labor, Premature Birth
Interventions
Gabapentin
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Sep 22, 2026, 9:05 PM EDT
Completed Phase 3 Interventional

Gabapentin to Treat Itch in Patients With Liver Disease

NCT00058890
View directory record Official record
Conditions
Liver Disease, Cholestasis, Cirrhosis, Pruritus, Itching
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 22, 2026, 9:05 PM EDT
Completed Not applicable Interventional Results available

Steroids Versus Gabapentin

NCT01495923
View directory record Official record
Conditions
Sciatica, Radiculopathy
Interventions
epidural steroid injection, Sham epidural steroid injection, Gabapentin, Placebo gabapentin
Procedure · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
17 Years to 100 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
San Diego, California • Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 22, 2026, 9:05 PM EDT
Recruiting Phase 4 Interventional

Feasibility of Early Gabapentin as an Intervention for Neurorecovery

NCT05302999
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 22, 2026, 9:05 PM EDT
Completed Not applicable Interventional Results available

Engaging Patients to Promote Deprescribing

NCT04294901
View directory record Official record
Conditions
Medical Overuse, Inappropriate Prescribing, Deprescriptions
Interventions
Direct to patient medication brochure
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
5,946 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Leeds, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Sep 22, 2026, 9:05 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Vasomotor Symptoms and Cardiovascular Control

NCT02202707
View directory record Official record
Conditions
Vasomotor Symptoms, Cardiovascular Health
Interventions
Gabapentin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
45 Years to 58 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Sep 22, 2026, 9:05 PM EDT
Completed Early Phase 1 Interventional

Improving Pain and Reducing Opioid Use (IPaRO) in Lumbar Spine Surgery Patients

NCT03088306
View directory record Official record
Conditions
Lumbar Spinal Stenosis, Lumbar Spinal Instability, Lumbar Spine Degeneration
Interventions
Standard analgesia use [Oxygen], Standard analgesia use [Hydromorphone], Standard analgesia use [Volatile Anesthesia], Standard analgesia use [Fentanyl], Multi-modal pain management [Acetaminophen + Gabapentin], Multi-modal pain management [Fentanyl], Multi-modal pain management [Intravenous Ketamine], Multi-modal pain management [Valium + Gabapentin]
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Sep 22, 2026, 9:05 PM EDT
Completed Phase 4 Interventional Results available

Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study

NCT01668667
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
GSK1838262 600 mg, GSK1838262 450 mg, GSK1838262 300 mg, GSK1838262 Placebo match
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
42
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Sep 22, 2026, 9:05 PM EDT
Completed Phase 4 Interventional Results available

An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain

NCT00385671
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
duloxetine hydrochloride, pregabalin, gabapentin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
5
States / cities
Torrance, California • Cromwell, Connecticut • Staten Island, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Sep 22, 2026, 9:05 PM EDT
Recruiting Phase 4 Interventional

Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease

NCT03082755
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Gabapentin Enacarbil, Placebo Oral Tablet
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
55 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Sep 22, 2026, 9:05 PM EDT
Completed Phase 3 Interventional Results available

Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance

NCT00748098
View directory record Official record
Conditions
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions
GSK1838262 Extended Release Tablets, Placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
24
States / cities
Jasper, Alabama • San Diego, California • Hallandale, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2013 · Synced Sep 22, 2026, 9:05 PM EDT
Completed Phase 3 Interventional

A Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance

NCT00667108
View directory record Official record
Conditions
Transient Insomnia
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
8
States / cities
Anaheim, California • San Diego, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 22, 2026, 9:05 PM EDT
Completed Not applicable Interventional

Opioid-Free Orthopaedic Surgery

NCT04176783
View directory record Official record
Conditions
Pain Management
Interventions
Opioids, Opioid-Free
Drug
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Sep 22, 2026, 9:05 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Gabapentin Treatment of Benzodiazepine Dependence

NCT01893632
View directory record Official record
Conditions
Benzodiazepine Dependence
Interventions
gabapentin, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 22, 2026, 9:05 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Gabapentin in Postherpetic Neuralgia

NCT00335933
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
Gabapentin extended-release tablets
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2007 · Synced Sep 22, 2026, 9:05 PM EDT
Completed Not applicable Interventional Results available

The Effect of Horizant (Gabapentin Enacarbil) on Augmentation

NCT02642315
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Horizant
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 22, 2026, 9:05 PM EDT
Completed Phase 4 Interventional Results available

Effect of Perioperative Gabapentin on Postoperative Opioid Requirements

NCT05494385
View directory record Official record
Conditions
Postoperative Pain
Interventions
Preoperative Gabapentin/Postoperative Placebo, Preoperative Gabapentin/Postoperative Gabapentin
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Sep 22, 2026, 9:05 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of Gabapentin to Decrease Postoperative Delirium and Pain

NCT00221338
View directory record Official record
Conditions
Postoperative Delirium, Postoperative Pain, Opioid Use, Hospital Length of Stay
Interventions
Gabapentin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Sep 22, 2026, 9:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users

NCT06247488
View directory record Official record
Conditions
Abuse Potential
Interventions
Placebo, Oxycodone 20 mg, GE-IR 200 mg, GE-IR 450 mg
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced Sep 22, 2026, 9:05 PM EDT
Completed Phase 4 Interventional Results available

Pregabalin vs. Gabapentin on Reducing Opioid Usage

NCT04705480
View directory record Official record
Conditions
Analgesics, Gabapentin, Injuries, Narcotics, Pain, Trauma
Interventions
Pregabalin 50mg, Gabapentin 300mg, Neither Pregabalin nor Gabapentin
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 22, 2026, 9:05 PM EDT